---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027349"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:13:45.329838+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma Q2 net loss $6.1M; FDA sets 700-patient bar for MAT2203 first-line

## Summary
- Q2 2023 revenue $0 (vs $1.1M in Q2 2022); net loss $6.1M ($0.03/sh) vs $5.9M.
- Cash and securities $22.5M at June 30, down from $28.8M; runway into Q3 2024.
- FDA requires ~700-patient non-inferiority trial (10% mortality margin) for first-line MAT2203 approval.
- Compassionate use: 15-year-old with leukemia and resistant mucor/aspergillus improved on MAT2203, no nephrotoxicity.
- Internal RNAi show in vitro activity; in vivo oral LNC data expected H2 2023.

## SEC filing metadata
- accession: 0001493152-23-027349
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315223027349/0001493152-23-027349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315223027349/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027349
- JSON: https://secwatch.observer/filing/0001493152-23-027349.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027349.txt

## Key facts
- Earnings Releases
  Matinas BioPharma Holdings, Inc. reported the three and six months ended June 30, 2023 results: revenue no revenue.
  - Period: the three and six months ended June 30, 2023
  - Revenue: no revenue
  - Result: reported results
  source text: Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three and six months ended June 30, 2023 and provides a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315223027349/0001493152-23-027349-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.